Michel Sade­lain puts his name and new cell en­gi­neer­ing tech be­hind 'ag­nos­tic' CAR-T start­up chas­ing epi­ge­net­ic anti­gens

It felt nat­ur­al for Alain Maiore and Se­bas­t­ian Amigore­na to bring in Michel Sade­lain as a co-founder of Mnemo Ther­a­peu­tics. A CAR-T pi­o­neer, Sade­lain had been in­volved as an ad­vi­sor since the ear­ly days — en­thu­si­as­tic about Amigore­na’s work in a ge­net­ic knock­out that could en­hance T cell mem­o­ry and a new class of po­ten­tial tar­gets he’s dis­cov­ered — and could in­tro­duce some well-known tech­nolo­gies to the tool­box. So they got the ini­tial cash from Sofinno­va Part­ners to plant roots in Paris and New York in ear­ly 2019; with­in a few months, they be­gan to see more clear­ly just what the anti­gen dis­cov­ery plat­form might un­lock.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.